Jacinto López Sagaseta: Solving the Structural Puzzle of FVIIa–EPCR Interaction
Jacinto López Sagaseta, Unit of Protein Crystallography and Structural Immunology-Navarrabiomed, shared a post on LinkedIn about a recent article he and his colleagues co-authored published in Blood Advances, adding:
“Recombinant factor VIIa (rFVIIa) is an important clinical intervention for severe bleeding, but some aspects associated with its mechanism of action have remained unresolved.
In 2007, several groups reported that FVIIa directly binds EPCR, an endothelial receptor, with consequences for the hemostatic effect of rFVIIa.
Despite extensive investigation, the structural basis of this interaction had remained elusive.
In this work, we report the experimental structure of the FVIIa Gla domain bound to EPCR, providing a missing structural piece in the study of FVIIa.
This is a particularly intricate protein complex, as it involves several residues of y-carboxyglutamate-an unusual yet naturally occurring amino acid, divalent ions, and a phospholipid molecule.
As such, it may also represent an interesting case for AI-based protein structure prediction and associated computational resources.
We are pleased to place this work in the context of the earlier study (2002) by Ogannesyan et al, who solved the structure of the protein C Gla domain bound to the same receptor, a landmark contribution to the structural biology of coagulation.
We would also like to thank the staff of the Xaira and Xaloc beamlines at the ALBA Synchrotron.
Further details can be found in the publication.”
Title: Structure of factor VII Gla domain bound to EPCR
Authors: Jacinto López-Sagaseta, María Gilda, Dichiara-Rodríguez

Title: The Crystal Structure of the Endothelial Protein C Receptor and a Bound Phospholipid
Authors: Vaheh Oganesyan, Natalia Oganesyan, Simon Terzyan, Zbigniew Dauter, Naomi L. Esmon, Charles T. Esmon
Read the Full Article on The Journal of Biological Chemistry

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery